全文获取类型
收费全文 | 398篇 |
免费 | 23篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 22篇 |
妇产科学 | 4篇 |
基础医学 | 54篇 |
口腔科学 | 7篇 |
临床医学 | 73篇 |
内科学 | 81篇 |
皮肤病学 | 9篇 |
神经病学 | 10篇 |
特种医学 | 85篇 |
外科学 | 28篇 |
综合类 | 22篇 |
预防医学 | 13篇 |
眼科学 | 6篇 |
药学 | 45篇 |
中国医学 | 1篇 |
肿瘤学 | 20篇 |
出版年
2022年 | 2篇 |
2021年 | 8篇 |
2019年 | 4篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 4篇 |
2015年 | 11篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 9篇 |
2011年 | 7篇 |
2010年 | 16篇 |
2009年 | 22篇 |
2008年 | 4篇 |
2007年 | 43篇 |
2006年 | 15篇 |
2005年 | 14篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 13篇 |
1998年 | 28篇 |
1997年 | 37篇 |
1996年 | 26篇 |
1995年 | 22篇 |
1994年 | 12篇 |
1993年 | 24篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 19篇 |
1988年 | 7篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 12篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1969年 | 2篇 |
1966年 | 1篇 |
1960年 | 1篇 |
1959年 | 1篇 |
1903年 | 1篇 |
排序方式: 共有482条查询结果,搜索用时 15 毫秒
61.
Incidence, clinical significance and prognosis of ventricular fibrillation in the early phase of myocardial infarction 总被引:1,自引:1,他引:1
DUBOIS CH.; SMEETS J. P.; DEMOULIN J. CL.; PIERARD L.; FOIDART G.; HENRARD L.; TULIPPE CH.; PRESTON L.; CARLIER J.; KULBERTUS H. E. 《European heart journal》1986,7(11):945-951
Of 1265 patients admitted to the CCU with the diagnosis of acuteMI, 96 (7.6%) developed ventricular fibrillation within 72 hoursfollowing admission. Of these 96, 35 (36.5%) had secondary VFassociated with left ventricular failure; they had a high in-hospitalmortality of 57.1%. The remaining 61 (63.5%) had primary VF,i.e. VF occurring in the absence of significant LV failure.Fourteen of these (23%) died in hospital: 9 due to PVF (3 duringthe first episode, 6 during a recurrence). This mortality figurewas significantly higher (P<0.001) than the mortality of10% seen among patients who did not experience VF. Primary VFshowed a recurrence rate of 20%. Compared with the 1061 patientswho left the hospital without primary VF, the 61 subjects withthis rhythm disorder were older, had larger infarcts and morefrequent complications, such as pericarditis, conduction abnormalities,frequent ventricular premature contractions and signs of rightventricular failure. These findings, in contrast with a widelyheld view, suggest that primary VFmay carry a guarded prognosis. 相似文献
62.
To determine the relationship between equilibrium binding of thrombin to sites on the platelet surface and the cleavage of membrane glycoprotein V (GPV) by thrombin, we examined the effect of active site- modified thrombin (1-chloro-3-tosylamido-7-amino-L-2-heptanone thrombin toslysCH2-thrombin) on the binding of native thrombin to platelets and on the hydrolysis of GPV by native thrombin. ToslysCH2-thrombin inhibited binding of native thrombin to high affinity sites on the platelet surface. In contrast, hydrolysis of GPV by native thrombin, even at threshold thrombin concentrations, was not inhibited by pretreatment with toslysCH2-thrombin at concentrations up to 210 nmol/L. ToslysCH2-thrombin also had no appreciable effect on platelet aggregation or release of 14C-serotonin induced by native thrombin. Because toslysCH2-thrombin does not inhibit platelet release, aggregation, or GPV hydrolysis by native thrombin but does inhibit high affinity surface binding by native thrombin, these results indicate that thrombin binding and hydrolysis of GPV are separate and unrelated events. 相似文献
63.
64.
65.
66.
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry 总被引:8,自引:1,他引:8
Nistico L; Buzzetti R; Pritchard LE; Van der Auwera B; Giovannini C; Bosi E; Larrad MT; Rios MS; Chow CC; Cockram CS; Jacobs K; Mijovic C; Bain SC; Barnett AH; Vandewalle CL; Schuit F; Gorus FK; Tosi R; Pozzilli P; Todd JA 《Human molecular genetics》1996,5(7):1075-1080
Susceptibility to autoimmune insulin-dependent (type 1) diabetes mellitus
is determined by a combination of environmental and genetic factors, which
include variation in MHC genes on chromosome 6p21 (IDDM1) and the insulin
gene on chromosome 11p15 (IDDM2). However, linkage to IDDM1 and IDDM2
cannot explain the clustering of type 1 diabetes in families, and a role
for other genes is inferred. In the present report we describe linkage and
association of type 1 diabetes to the CTLA-4 gene (cytotoxic T lymphocyte
associated-4) on chromosome 2q33 (designated IDDM12). CTLA-4 is a strong
candidate gene for T cell- mediated autoimmune disease because it encodes a
T cell receptor that mediates T cell apoptosis and is a vital negative
regulator of T cell activation. In addition, we provide supporting evidence
that CTLA-4 is associated with susceptibility to Graves' disease, another
organ- specific autoimmune disease.
相似文献
67.
68.
69.
Zollikofer CL; Cragg AH; Einzig S; Castaneda-Zuniga WR; Castaneda F; Rysavy JA; Bruhlmann WF; Shebuski RJ; Amplatz K 《Radiology》1983,149(3):681-685
To prevent platelet aggregation following percutaneous transluminal angioplasty (PTA), cyclooxygenase inhibitors such as acetylsalicylic acid (ASA) and indomethacin are recommended. However, ASA blocks both the proaggregating effects of thromboxane (TXA2) and the antiaggregating and vasodilating effects of prostacyclin (PGI2). The authors measured the contractile response of dilated canine carotid arteries in situ and in vitro using an isometric force transducer. Following PTA, contraction of the arterial wall was significantly reduced (p less than 0.01). By blocking cyclooxygenase with indomethacin (3 micrograms/ml), contraction was greatly improved (p less than 0.001). These results suggest that PTA may result in marked release of prostacyclin by the damaged arterial wall, which could account for the decreased responsiveness of the artery to exogenous norepinephrine. 相似文献
70.
CL Martyn-Simmons L Green G Ash RW Groves CH Smith JNWN Barker 《Journal of the European Academy of Dermatology and Venereology》2009,23(12):1394-1397
Background Targeted biologic therapies have made a significant impact on the treatment for moderate to severe psoriasis. In the United Kingdom, the National Institute for Health and Clinical Excellence recommends etanercept, a human recombinant tumour necrosis factor (TNF) receptor fusion protein, for moderate to severe psoriasis patients who have failed conventional therapies. There is, however, no data available on the role of other TNF antagonists for patients who have failed etanercept. Adalimumab, a fully human, anti-TNF monoclonal antibody, is approved for treatment of moderate to severe psoriasis.
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献